ADP-TILIL7
Phase 1
- Conditions
- ocally advanced or metastatic melanomaMedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025671Term: Malignant melanoma stage IV Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-509665-20-00
- Lead Sponsor
- Herlev Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie IL7-modified TIL therapy in CTIS2023-509665-20-00 for stage III/IV melanoma?
How does IL7-enhanced TIL therapy compare to anti-PD-1 checkpoint inhibitors in metastatic melanoma clinical trials?
Which biomarkers correlate with response to IL7-modified TILs in Herlev Hospital's phase I melanoma trial CTIS2023-509665-20-00?
What are the potential cytokine release syndrome risks and mitigation strategies for IL7-TIL therapy in CTIS2023-509665-20-00?
Are there synergistic combination approaches involving IL7-TILs and BRAF/MEK inhibitors for advanced melanoma treatment?